moroctocog alfa: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
moroctocog alfa: clinical details
Prescribing considerations
- Initiate and supervise treatment through clinicians experienced in haemophilia A.
- Individual response varies; assess clinical response and factor VIII recovery rather than relying on body weight alone.
- It is not indicated for von Willebrand disease.
- Consider cardiovascular risk factors and complications associated with central venous access devices.
- Account for sodium exposure where clinically relevant, particularly when several syringes are required.
- Record the product name and batch number for biological-product traceability.
Contraindications and cautions
- Hypersensitivity to moroctocog alfa or any excipient
- Known allergy to hamster protein
Monitoring
- Monitor factor VIII activity and clinical haemostatic response.
- The chromogenic assay is recommended; one-stage assay results may be reagent- and standard-dependent and can read lower.
- Test for factor VIII inhibitors if expected activity is not achieved or bleeding remains uncontrolled.
- Monitor for hypersensitivity during administration and catheter-related infection or thrombosis when applicable.
Clinical pharmacology
Moroctocog alfa is a B-domain-deleted recombinant human factor VIII produced in Chinese hamster ovary cells. After infusion it binds circulating von Willebrand factor and functions as a cofactor in factor X activation, temporarily correcting factor VIII deficiency.
Formulation and product differences
- The selected presentation is a dual-chamber pre-filled syringe containing freeze-dried powder and sodium chloride solvent.
- The manufacturing process uses no added human- or animal-derived protein during cell culture, purification or final formulation, although trace hamster proteins may remain.
- Use the supplied infusion set because adsorption to some equipment may reduce delivered factor VIII.
- The reconstituted product contains no preservative and should be used promptly in accordance with the product instructions.
moroctocog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 250 units, 500 units, 1000 units, 2000 units, 3000 units
moroctocog alfa interactions
No direct interactions between recombinant factor VIII products and other medicines have been reported. However, medicines that increase bleeding risk still require review because of the underlying bleeding disorder.
Aspirin and non-steroidal anti-inflammatory drugs, such as ibuprofen or naproxen
These may increase bleeding or bruising and should not be started without agreement from the haemophilia team.
Anticoagulants, such as warfarin, heparin, apixaban or rivaroxaban
These can increase bleeding risk and require specialist assessment if clinically necessary.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.